DL
David E. Lazar
10% Owner

David E. Lazar insider trades: Cyclacel Pharmaceuticals (CYCC) stock buys and sales

10% Owner, Cyclacel Pharmaceuticals Last trade Jul 30, 2025 30 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2022
12
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

and 6 more companies

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 30, 2025CYCC↓ Sell$83K
Feb 26, 2025CYCC↓ Sell$5.5M
Dec 26, 2024MINM↑ Buy$50K
Jun 21, 2023TTNP↓ Sell$4.2M
Jun 21, 2023TTNP↓ Sell$442K
Jan 25, 2023TTNP↑ Buy$56K
Jul 7, 2022TTNP↑ Buy$1.6M
Jul 6, 2022TTNP↑ Buy$282K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About David E. Lazar's insider trades

David E. Lazar is a 10% owner of Cyclacel Pharmaceuticals (CYCC). Since Jul 6, 2022, David has reported 4 open-market purchases worth $2.0M and 4 sales worth $10.2M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (14 filings), other transactions (9 filings), conversions (3 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CYCC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.